1. 2500 Orteronel (Ort) maintenance therapy in patients (pts) with metastatic castration resistant prostate cancer (mCRPC) and non-progressive disease after first-line docetaxel (Doc) therapy: Results of a multicenter randomized double-blind placebo-controlled phase III trial (SAKK 08/11). Issue 3 (September 2015) Authors: Cathomas, R.; Crabb, S.; Kenner, H.; Mark, M.; Rothermundt, C.; Elliott, T.; Winterhalder, R.; Von Burg, P.; Berardi Vilei, S.; Hayoz, S.; Rauch, D.; Roggero, E.; Stenner, F.; Berthold, D.; Erdmann, A.; Fischer, N.; Manetsch, G.; Gillessen, S. Journal: European journal of cancer Issue: Volume 51:Issue 3(2015:Feb.) Page Start: S473 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗